EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Male Predominance in HBV-Related Hepatocellular Carcinoma: Unraveling the Axis of Androgen Receptor, Viral Replication, and Immune Evasion via NKG2D Ligands

Koji Takahashi, Takaaki Ikegami, Arisa Kato, Nana Yamada, Terunao Iwanaga, Takafumi Sakuma, Junichi Senoo, Hidehiro Kamezaki

Onco · 01.03.2026 · 6 (1) · 15

DOI: 10.3390/onco6010015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Onco, online erschienen am 01.03.2026. Verfasst von Koji Takahashi und 7 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) exhibits a striking male predominance, particularly in Hepatitis B Virus (HBV) endemic regions. While lifestyle factors and estrogen protection are traditional explanations, they fail to fully account for this disparity. This review elucidates the molecular mechanisms driving this gender gap, focusing on the interplay between the Androgen Receptor (AR), viral replication, and the suppression of NKG2D-mediated immune surveillance. We synthesized experimental and clinical findings linking AR signaling, the viral protein HBx, and the regulation of NKG2D ligands (MICA/MICB). Current evidence identifies a positive feedback loop where AR enhances HBV replication, while HBx amplifies AR activity. Crucially, this axis systematically dismantles innate immunity: AR signaling represses MICA/B transcription via miRNA networks and upregulates ADAM metalloproteases, leading to ligand shedding and the release of soluble MICA (sMICA), effectively blinding Natural Killer (NK) cells. We propose that historical failures of anti-androgen monotherapy likely stemmed from ignoring this immune modulation. Consequently, targeting the AR-NKG2D axis represents a promising strategy to sensitize tumors to immunotherapy, suggesting that future therapeutic approaches should combine AR modulation with immune checkpoint inhibitors or shedding-blockade.

Zitieren

APA

Takahashi, K., Ikegami, T., Kato, A., Yamada, N., Iwanaga, T., Sakuma, T., Senoo, J., & Kamezaki, H. (2026). The Male Predominance in HBV-Related Hepatocellular Carcinoma: Unraveling the Axis of Androgen Receptor, Viral Replication, and Immune Evasion via NKG2D Ligands. Onco, 6(1), 15. https://doi.org/10.3390/onco6010015

Vancouver

Takahashi K, Ikegami T, Kato A, Yamada N, Iwanaga T, Sakuma T, et al. The Male Predominance in HBV-Related Hepatocellular Carcinoma: Unraveling the Axis of Androgen Receptor, Viral Replication, and Immune Evasion via NKG2D Ligands. Onco. 2026;6(1):15. doi:10.3390/onco6010015

BibTeX
@article{Takahashi2026,
  author = {Takahashi, Koji and Ikegami, Takaaki and Kato, Arisa and Yamada, Nana and Iwanaga, Terunao and Sakuma, Takafumi and Senoo, Junichi and Kamezaki, Hidehiro},
  title = {The Male Predominance in HBV-Related Hepatocellular Carcinoma: Unraveling the Axis of Androgen Receptor, Viral Replication, and Immune Evasion via NKG2D Ligands},
  journal = {Onco},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {15},
  doi = {10.3390/onco6010015}
}
Kostenlos starten →